Compare Procter & Gamble Health with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs LUPIN - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH LUPIN PROCTER & GAMBLE HEALTH/
LUPIN
 
P/E (TTM) x 51.2 109.7 46.7% View Chart
P/BV x 4.5 2.5 179.0% View Chart
Dividend Yield % 10.6 0.0 -  

Financials

 PROCTER & GAMBLE HEALTH   LUPIN
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
LUPIN
Mar-19
PROCTER & GAMBLE HEALTH/
LUPIN
5-Yr Chart
Click to enlarge
High Rs3,549986 359.9%   
Low Rs1,301720 180.6%   
Sales per share (Unadj.) Rs511.4369.5 138.4%  
Earnings per share (Unadj.) Rs61.313.4 457.2%  
Cash flow per share (Unadj.) Rs74.037.4 198.0%  
Dividends per share (Unadj.) Rs440.000-  
Dividend yield (eoy) %18.10-  
Book value per share (Unadj.) Rs927.8303.7 305.5%  
Shares outstanding (eoy) m16.60452.49 3.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.72.3 205.3%   
Avg P/E ratio x39.663.6 62.2%  
P/CF ratio (eoy) x32.822.8 143.6%  
Price / Book Value ratio x2.62.8 93.0%  
Dividend payout %717.90-   
Avg Mkt Cap Rs m40,257386,064 10.4%   
No. of employees `0001.117.7 6.4%   
Total wages/salary Rs m1,31331,513 4.2%   
Avg. sales/employee Rs Th7,486.79,453.8 79.2%   
Avg. wages/employee Rs Th1,157.61,782.0 65.0%   
Avg. net profit/employee Rs Th897.2343.0 261.6%   
INCOME DATA
Net Sales Rs m8,490167,182 5.1%  
Other income Rs m2443,640 6.7%   
Total revenues Rs m8,734170,822 5.1%   
Gross profit Rs m1,48228,822 5.1%  
Depreciation Rs m21110,850 1.9%   
Interest Rs m03,078 0.0%   
Profit before tax Rs m1,51418,534 8.2%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m66-3,400 -1.9%   
Tax Rs m5639,017 6.2%   
Profit after tax Rs m1,0176,066 16.8%  
Gross profit margin %17.517.2 101.2%  
Effective tax rate %37.148.7 76.4%   
Net profit margin %12.03.6 330.3%  
BALANCE SHEET DATA
Current assets Rs m15,343138,536 11.1%   
Current liabilities Rs m1,96061,299 3.2%   
Net working cap to sales %157.646.2 341.2%  
Current ratio x7.82.3 346.3%  
Inventory Days Days4984 58.2%  
Debtors Days Days28112 25.3%  
Net fixed assets Rs m1,209127,516 0.9%   
Share capital Rs m166905 18.3%   
"Free" reserves Rs m15,235136,517 11.2%   
Net worth Rs m15,401137,422 11.2%   
Long term debt Rs m066,417 0.0%   
Total assets Rs m17,595279,494 6.3%  
Interest coverage xNM7.0-  
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x0.50.6 80.7%   
Return on assets %5.83.3 176.7%  
Return on equity %6.64.4 149.7%  
Return on capital %10.38.9 115.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,63659,414 2.8%   
Fx outflow Rs m4,36822,282 19.6%   
Net fx Rs m-2,73237,132 -7.4%   
CASH FLOW
From Operations Rs m-1,30416,660 -7.8%  
From Investments Rs m12,697-32,825 -38.7%  
From Financial Activity Rs m-3017,441 -4.0%  
Net Cashflow Rs m11,093-8,724 -127.2%  

Share Holding

Indian Promoters % 0.0 46.6 -  
Foreign collaborators % 51.8 0.2 25,900.0%  
Indian inst/Mut Fund % 18.2 11.3 161.1%  
FIIs % 1.0 31.9 3.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 10.1 288.1%  
Shareholders   28,591 98,259 29.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   FDC LTD.  UNICHEM LAB  WYETH LTD  ELDER PHARMA  ALEMBIC LTD  

Compare PROCTER & GAMBLE HEALTH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Rising Inflation and Onion Effect: Your Inside Scoop on the Markets(Podcast)

Stock markets remained rangebound this week too. Macroeconomic news globally and domestically remained the focus of the week.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Use My Secret to Increase Your Trading Profits Today

Dec 10, 2019

What to do after every trade.

How We Made 14.64% Trading Profit in Just 2 Days

Dec 12, 2019

A high probability trade that worked to perfection for my subscribers.

Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020(Profit Hunter)

Dec 5, 2019

This corner of the market could provide more returns than blue chips in 2020.

Make the Most of the Smallcap Rebound with These Stocks(Profit Hunter)

Dec 3, 2019

Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.

What Is the IPO Euphoria Signaling Us About the Markets?(The 5 Minute Wrapup)

Dec 2, 2019

2019 will be remembered as the year of great money-making IPOs...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Dec 13, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 5-YR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS